Buy Glenmark Pharmaceuticals ; target of Rs 1100: Axis Direct
Axis Direct is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1100 in its research report dated March 24, 2017.
June 09, 2017 / 10:55 AM IST
Axis Direct's report on Glenmark Pharmaceuticals
Increase in inventory from Rs 12.7 bn (60 days’ sales) in FY15 to Rs15.7 bn (68 days’ sales) in FY16 owing to build-up of gZetia supplies (~Rs1.5 bn). Additionally, with channel consolidation and generics pricing trending lower in the US, Glenmark is trying to maintain/improve its market share in existing products (see Appendix), which also lead to some inventory build-up (Rs1bn) and increase in receivables.
We upgraded Glenmark to BUY (Oct 28, 2016), as we believed it is in sweet spot given improvement in its key markets (US, India, Russia) –posted 18% revenue growth 9MFY17 (ex-gZetia) and as we expected the momentum to continue (projected 14% revenue growth & 450 bps EBITDA margin expansion to 23.3% over FY16-19E) along with reduction in net debt (given gZetiaone-offs).
For all recommendations, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.